Joint project
PACE BamA inhibitors - Novel drugs against Gram-negative bacterial pathogens
Funder: UK Research and Innovation; LifeArc
Period: 2025-2027
Abstract:
Justus-Liebig-University Giessen (“JLU”), Germany won a £1 million grant from PACE (Pathways to Antimicrobial Clinical Efficacy), to develop a first-in-class BamA inhibitor targeting multi-drug-resistant (MDR) Gram-negative pathogens in collaboration with U.K. Infex Therapeutics, an anti-infectives specialist.
Cooperation partners with funding
- Infex Therapeutics
